KITE-363 is under clinical development by Gilead Sciences and currently in Phase I for Unspecified B-Cell Lymphomas.

Tevimbra is under clinical development by BeiGene and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData, Phase II drugs for Mantle Cell Lymphoma have a 31% phase transition ...

Regulators approved the first bespoke cell therapies for solid tumors this year, while drugmakers expanded and improved upon ...

The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab (Blincyto) to chemotherapy ...

Blinatumomab in addition to standard chemotherapy improved pediatric patients with NCI standard-risk B-cell acute lymphoblastic leukemia survival outcomes.

NX-5948 has received fast track designation for adults with relapsed or refractory Waldenström macroglobulinemia who received ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has earned a consensus rating of “Moderate Buy” from the eleven analysts that are covering the stock, Marketbeat Ratings reports. Three ...

Bicistronic CAR T-cell therapy can produce durable complete responses in pediatric patients with relapsed or refractory B-ALL, data suggest.

Douglas Richmond is seeking compassionate due to his daughter's leukemia. But in Tennessee such a process doesn't exist.

A trio of experts discuss the treatment of chronic lymphocytic leukemia (CLL) and mantle cell lymphoma (MCL) with Bruton ...

This year’s most-read articles on chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) explored treatment ...

CURE® highlights some top stories from the ASH Annual Meeting, focusing on B-cell acute lymphoblastic leukemia, multiple ...